Vistagen therapeutics stock.

Investors Mark Flather Vice President, Investor Relations, VistaGen Therapeutics Phone: (650) 577-3617 Email: [email protected]. Media Nate Hitchings SKDK [email protected] to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00.The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that safety and exploratory efficacy data from its Phase 3 open-label study of fasedienol (PH94B) nasal …VistaGen Therapeutics on Monday posted positive topline data from the Phase III PALISADE-2 trial, showing that its investigational nasal spray fasedienol met its primary endpoint, strongly easing distress among patients with social anxiety disorder. The market reacted enthusiastically to the news, sending VistaGen’s stock soaring around …

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …Advertisement Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After...

Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...

VistaGen Therapeutics ( NASDAQ: VTGN) jumped ~17% on Wednesday morning after announcing data from a Phase 3 trial for its experimental nasal spray for social anxiety disorder (SAD), fasedienol ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ...The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023.The analyst firm set a price target for $30.00 expecting VTGN to rise to within ...3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and …Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ...

On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.

Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. VistaGen Therapeutics, Inc. Common Stock (VTGN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...VistaGen Therapeutics (VTGN) In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $30.00. The company’s shares ...VistaGen Therapeutics Inc stock performance at a glance. Check VistaGen Therapeutics Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. VistaGen Therapeutics Inc 50-day moving average is $3.73.Next quarter’s earnings estimate for VTGN is -$0.68 with a range of -$0.68 to -$0.68. The previous quarter’s EPS was -$0.94. VTGN beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the …

Mar 9, 2023 · Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 thousand and a GAAP net loss of $9.76 million. William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.. The lead product Fasedienol (PH94B), is an intranasal pherine and is in late-stage development …VTGN Earnings Date and Information. Vistagen Therapeutics last issued its quarterly earnings results on November 9th, 2023. The reported ($0.66) earnings per share for the quarter. The company earned $0.28 million during the quarter. Vistagen Therapeutics has generated $0.00 earnings per share over the last year.fink. 10/14/23 1:04 PM. Post #4,990. Re: #4,989: @The_Q - A buddy told me this stock is $50-70. They have an impressive pipeline. But it's a pharma play. A time suck. They are in phase 3 for their first drug. Once they get those results they will submit to the FDA for approval.Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...

Dec 21, 2022 · Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline. SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Dec. 21, 2022-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to ...

Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. VistaGen Therapeutics, Inc. Common Stock (VTGN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data ...H Snodgrass VTGN stock SEC Form 4 insiders trading. H has made over 3 trades of the VistaGen Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of VTGN stock worth $10,238 on 17 August 2021.. The largest trade he's ever made was buying 15,000 units of VistaGen …If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …Jun 30, 2021 · Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ... The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing ...

Dec 6, 2022 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ...

Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...

Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year ...What is Vistagen Therapeutics, Inc. (VTGN)'s stock price history? Over the last year, Vistagen Therapeutics, Inc.’s stock price has decreased by 7.38%. Vistagen Therapeutics, Inc. is currently ... Nov 10, 2022 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago. VistaGen Therapeutics Stock Prediction 2030. In 2030, the VistaGen Therapeutics stock will reach $ 228.74 if it maintains its current 10-year average growth rate. If this VistaGen Therapeutics stock prediction for 2030 materializes, VTGN stock willgrow 6,271.71% from its current price. Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.Nov 30, 2023 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Vistagen Therapeutics stock is Buy based on the current 2 buy ratings for VTGN. The average twelve-month price prediction for Vistagen Therapeutics is $21.00 with a high price target of $30.00 and a low price target of $12.00. Vistagen Therapeutics is a biopharmaceutical company that develops products for anxiety, depression, and CNS disorders. The stock has a consensus rating …At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ...

Aug 7, 2023 · Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ... 3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and welcome to today’s Vistagen Fiscal Year ...About the VistaGen Therapeutics, Inc. stock forecast. As of 2023 November 29, Wednesday current price of VTGN stock is 3.600$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. VistaGen Therapeutics stock price as been showing a rising tendency so we believe …Instagram:https://instagram. vcsa stock priceusaa motorcycle quotehulu.cancelvti top 25 holdings Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of …Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » VTGN Vistagen Therapeutics, Inc. … how to make money using forexbuy sq Biotech Firm Pops 677% on Social Anxiety Spray Trial Success. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits ...Apple Inc. Common Stock. $191.6541 +1.9641 +1.04%. VistaGen Therapeutics, Inc. Common Stock (VTGN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data ... american builders insurance company VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin Pharmaceuticals, Inc., a privately held drug development company …William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ...